{
    "clinical_study": {
        "@rank": "119452", 
        "arm_group": [
            {
                "arm_group_label": "MLN9708 + 300mg/m^2 Cyclophosphamide", 
                "arm_group_type": "Experimental", 
                "description": "Induction: MLN9708 + Cyclophosphamide (300mg/m^2) + Dexamethasone. Maintenance: MLN9708."
            }, 
            {
                "arm_group_label": "MLN9708 + 400mg/m^2 Cyclophosphamide", 
                "arm_group_type": "Experimental", 
                "description": "Induction: MLN9708 + Cyclophosphamide (400mg/m^2) + Dexamethasone. Maintenance: MLN9708."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a phase 2, multicenter, open-label study in patients with NDMM who have not received\n      prior systemic treatment for multiple myeloma (MM) and who are ineligible for high-dose\n      therapy (HDT)-SCT due to age (ie, \u2265 65 years) or comorbid disease(s)."
        }, 
        "brief_title": "Phase 2 Study to Evaluate the Oral Combination of MLN9708 With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NDMM)", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adult male or female patients 18 years of age or older with a confirmed diagnosis of\n             symptomatic multiple myeloma (MM) according to standard criteria who have not\n             received prior treatment for MM.\n\n          2. Patients for whom cyclophosphamide and dexamethasone treatment is appropriate and who\n             are considered not eligible for HDT-SCT for 1 or more of the following reasons:\n\n               -  Patient is \u2265 65 years of age.\n\n               -  Patient is \u2264 65 years of age but has significant comorbid condition(s) that are,\n                  in the opinion of the investigator, likely to have a negative impact on\n                  tolerability of HDT-SCT.\n\n          3. Measurable disease as defined in the protocol.\n\n          4. Meets clinical laboratory values as defined in the protocol.\n\n          5. Eastern Cooperative Oncology Group performance status of 0, 1, or 2.\n\n          6. Female patients who are post menopausal, surgically sterile, or agree to practice 2\n             effective methods of contraception or agree to practice true abstinence.\n\n             Male patients who agree to practice effective barrier contraception or agree to\n             practice true abstinence.\n\n          7. Voluntary written consent.\n\n          8. Suitable venous access for the study-required blood sampling.\n\n          9. Patient is willing and able to adhere to the study visit schedule and other protocol\n             requirements.\n\n        Exclusion Criteria:\n\n        Patients meeting any of the following exclusion criteria are not to be randomized to\n        treatment:\n\n          1. Prior treatment for multiple myeloma with either standard of care treatment or\n             investigational regimen.\n\n          2. Diagnosis of smoldering MM, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy,\n             organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome,\n             plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or\n             myeloproliferative syndrome.\n\n          3. Central nervous system involvement.\n\n          4. Diagnosed or treated for another malignancy within 2 years before the first dose or\n             previously diagnosed with another malignancy and have any evidence of residual\n             disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are\n             not excluded if they have undergone complete resection.\n\n          5. Peripheral neuropathy Grade 1 with pain or \u2265 Grade 2 of any cause.\n\n          6. Known GI disease or GI procedure that could interfere with the oral absorption or\n             tolerance of study drug, including difficulty swallowing.\n\n          7. Infection requiring IV antibiotic therapy or other serious infection within 14 days\n             before the first dose of study drug.\n\n          8. Ongoing or active infection, known HIV positive, active hepatitis B or C infection\n\n          9. Systemic treatment with strong inhibitors of CYP1A2 or CYP3A, or strong CYP3A\n             inducers, or use of Ginkgo biloba or St. John's wort within 14 days before the first\n             dose of study treatment.\n\n         10. Known allergy to any of the study medications, their analogues, or excipients in the\n             various formulations.\n\n         11. Major surgery within 14 days before the first dose of study drug.\n\n         12. Female patients who are lactating and breastfeeding or pregnant.\n\n         13. Serious medical or psychiatric illness that could, in the investigator's opinion,\n             potentially interfere with the completion of treatment according to the protocol.\n\n         14. Comorbid systemic illnesses or other severe concurrent disease which, in the judgment\n             of the investigator, would make the patient inappropriate for entry into this study\n             or interfere significantly with the proper assessment of safety and toxicity of the\n             prescribed regimens.\n\n         15. Treatment with any investigational products for reasons other than MM within 30 days\n             before the first dose of study drug."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02046070", 
            "org_study_id": "C16020", 
            "secondary_id": "2013-003113-17"
        }, 
        "intervention": [
            {
                "arm_group_label": "MLN9708 + 300mg/m^2 Cyclophosphamide", 
                "description": "Induction. Days 1, 8, 15 and dexamethasone on days 1, 8, 15, 22. Repeat every 28 days for 13 cycles in the absence of progressive disease (PD)/death or unacceptable toxicity.", 
                "intervention_name": "Cyclophosphamide (300mg/m^2)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MLN9708 + 400mg/m^2 Cyclophosphamide", 
                "description": "Induction. Days 1, 8, 15 and dexamethasone on days 1, 8, 15, 22. Repeat every 28 days for 13 cycles in the absence of progressive disease (PD)/death or unacceptable toxicity.", 
                "intervention_name": "Cyclophosphamide (400mg/m^2)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MLN9708 + 300mg/m^2 Cyclophosphamide", 
                    "MLN9708 + 400mg/m^2 Cyclophosphamide"
                ], 
                "description": "Days 1, 8, 15 during 28-day cycles until PD/death or unacceptable toxicity", 
                "intervention_name": "MLN9708", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MLN9708 + 300mg/m^2 Cyclophosphamide", 
                    "MLN9708 + 400mg/m^2 Cyclophosphamide"
                ], 
                "description": "Days 1, 8, 15, 22. Repeat every 28 days for 13 cycles in the absence of progressive disease (PD)/death or unacceptable toxicity.", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Dexamethasone", 
                "Dexamethasone acetate", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "MLN9708", 
            "Newly diagnosed", 
            "NDMM"
        ], 
        "lastchanged_date": "April 9, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "state": "Attiki"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden", 
                        "state": "Sodermanlands lan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lund", 
                        "country": "Sweden"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Greece", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-Label, Phase 2 Study to Evaluate the Oral Combination of MLN9708 With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment", 
        "overall_contact": {
            "email": "medical@mlnm.com", 
            "last_name": "For an updated listing of recruitment sites contact: Millennium Medical and Drug Information Center", 
            "phone": "1-877-674-3784"
        }, 
        "overall_official": {
            "affiliation": "Millennium Pharmaceuticals, Inc.", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Combined response rate of CR (including sCR) + VGPR in patients treated with MLN9708 when added to a standard care regimen of Cyclophosphamide and Dexamethasone (Cd) during the induction phase", 
            "safety_issue": "No", 
            "time_frame": "28-day cycles of treatment of MLN9708 + Cyclophosphamide on days 1, 8, 15 and Dexamethasone on days 1, 8, 15, 22 for approximately 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02046070"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "All AEs, Grade 3 or higher AEs, AEs resulting in discontinuation, AEs resulting in dose reduction, serious adverse events (SAEs), and assessments of clinical laboratory values", 
                "safety_issue": "Yes", 
                "time_frame": "Recorded from the first dose of drug in the study drug regimen through 30 days after last dose of drug in the study drug regimen"
            }, 
            {
                "description": "Includes single-dose maximum (peak) concentration (Cmax), single-dose first time of occurrence of maximum (peak) concentration (Tmax), and area under the plasma concentration versus time curve (AUC)", 
                "measure": "PK parameters", 
                "safety_issue": "No", 
                "time_frame": "Days 1-3, 5, 8, 15-17, 19 and 22 during cycle 1 and day 1 of cycle 2 (safety lead-in patients) or days 1, 8, 15, and 22 during cycles 1-3 (excluding safety lead-in)"
            }, 
            {
                "measure": "ORR (Overall response rate, CR + VGPR + PR), CR, VGPR, and PR during the induction phase and throughout the entire study", 
                "safety_issue": "No", 
                "time_frame": "Time from the start of treatment to the occurrence of disease progression, unacceptable toxicities, discontinuation of study due to any other reasons, or end of study (EOS) up to 60 months"
            }, 
            {
                "measure": "Time to Response (TTR)", 
                "safety_issue": "No", 
                "time_frame": "Time from the date of enrollment to the date of first documented response during induction phase up to 36 months"
            }, 
            {
                "measure": "Duration of Response (DOR)", 
                "safety_issue": "No", 
                "time_frame": "Time interval from the date of first response to the date of disease progression up to 60 months"
            }, 
            {
                "measure": "Time to Progression (TTP)", 
                "safety_issue": "No", 
                "time_frame": "Time interval from the date of enrollment to the date of first documented disease progression up to 60 months"
            }, 
            {
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Time interval from the date of enrollment to the date of first documented disease progression or death up to 60 months"
            }, 
            {
                "measure": "AEs, SAEs, AEs resulting in discontinuation, AEs resulting in dose reduction in patients remaining on treatment after 13 cycles.", 
                "safety_issue": "Yes", 
                "time_frame": "From signing of the informed consent form through 30 days after the last dose of drug in the study drug regimen"
            }, 
            {
                "measure": "Comparison of change in global health status between baseline and each post-baseline assessment, as measured by the global health scale, functioning, and symptoms of the EORTC QLQ-C30 and MY-20", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of each 28-day cycle"
            }, 
            {
                "measure": "ORR, CR, VGPR, and PR of single agent MLN9708 as maintenance therapy in patients remaining on treatment after 13 cycles", 
                "safety_issue": "No", 
                "time_frame": "From signing of the informed consent form through 30 days after the last dose of drug in the study drug regimen"
            }
        ], 
        "source": "Millennium Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Millennium Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}